4D Molecular Therapeutics Inc (NASDAQ: FDMT) kicked off on Monday, down -13.77% from the previous trading day, before settling in for the closing price of $5.52. Over the past 52 weeks, FDMT has traded in a range of $5.22-$36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 151.75% over the last five years. While this was happening, its average annual earnings per share was recorded -12.46%. With a float of $38.13 million, this company’s outstanding shares have now reached $52.00 million.
The firm has a total of 147 workers. Let’s measure their productivity. In terms of profitability, gross margin is -43747.06%, operating margin of -990447.06%, and the pretax margin is -844000.0%.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 17.53%, while institutional ownership is 98.98%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.46% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Take a look at 4D Molecular Therapeutics Inc’s (FDMT) current performance indicators. Last quarter, stock had a quick ratio of 17.33.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Analysing the last 5-days average volume posted by the [4D Molecular Therapeutics Inc, FDMT], we can find that recorded value of 0.85 million was better than the volume posted last year of 0.83 million. As of the previous 9 days, the stock’s Stochastic %D was 22.63%. Additionally, its Average True Range was 0.50.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 0.67%, which indicates a significant decrease from 4.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.25% in the past 14 days, which was higher than the 71.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.09, while its 200-day Moving Average is $16.27. Now, the first resistance to watch is $5.15. This is followed by the second major resistance level at $5.54. The third major resistance level sits at $5.78. If the price goes on to break the first support level at $4.52, it is likely to go to the next support level at $4.28. Now, if the price goes above the second support level, the third support stands at $3.89.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
The company with the Market Capitalisation of 220.04 million has total of 46,228K Shares Outstanding. Its annual sales at the moment are 20,720 K in contrast with the sum of -100,840 K annual income. Company’s last quarter sales were recorded 10 K and last quarter income was -34,950 K.
